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Abstract Themultimeric plasma glycoprotein (GP) vonWillebrand factor (VWF) is best known for
recruiting platelets to sites of injury during primary hemostasis. Generally, mutations in
the VWF gene lead to loss of hemostatic activity and thus the bleeding disorder von
Willebrand disease. By employing cone and platelet aggregometry and microfluidic
assays, we uncovered a platelet GPIIb/IIIa-dependent prothrombotic gain of function
(GOF) for variant p.Pro2555Arg, located in the C4 domain, leading to an increase in
platelet aggregate size. We performed complementary biophysical and structural
investigations using circular dichroism spectra, small-angle X-ray scattering, nuclear
magnetic resonance spectroscopy, molecular dynamics simulations on the single C4
domain, and dimeric wild-type and p.Pro2555Arg constructs. C4-p.Pro2555Arg
retained the overall structural conformation with minor populations of alternative
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Introduction
VonWillebrand factor (VWF) plays a key role in hemostasis by
mediating platelet adhesion to the site of vascular injury and
by protecting factor VIII from rapid clearance in the circula-
tion.1,2 It is well accepted that mutations generally lead to
various VWF dysfunctions that result in the most common
bleeding disorder, von Willebrand disease (VWD). Severity is
variable, depending on themany particular molecular defects
of thismultidomain (►Fig. 1A) andmultifunctionalprotein.3–5
However, in recent years increasing evidence has been
gathered that VWF can also be regarded as a prothrombotic
factor. Stroke6 and thrombotic complications in sepsis,7
inflammation and infections, such as COVID-19,8 are associ-
ated with high plasma levels of VWF.
We have recently described the first gain-of-function (GOF)
variant of VWFwhich exhibits shear-dependent prothrombotic
characteristics. This common VWF variant, p.Phe2561Tyr
(rs35335161),playsasignificant role inprematureandrepeated
events of myocardial infarction (MI) in younger women as
shown in a cohort of the Ludwigshafen Risk and Cardiovascular
Health Study.9,10p.Phe2561Tyr is located in theVWFC4domain
(►Fig. 1B), harboring the RGD-binding sequence for platelet
receptor glycoprotein (GP) IIb/IIIa.11 Our functional and
structural studies have indicated that the Tyr2561 allele shifts
the onset of aggregation to lower shear rates compared to
Phe2561-VWF.10,12 TheGPIIb/IIIa-binding RGDmotif is situated
at the tip of a flexible and extended loop region within a β-
hairpin, which is one of the two layers of β-sheets in the first
subdomain (SD1) of C4. p.Phe2561Tyr is located in the second
subdomain (SD2) instead, close to theC-terminusof thedomain,
remote fromtheRGDmotif (►Fig. 1B) anddoesnot affectdirect
binding to GPIIb/IIIa under static conditions. Instead, the
Tyr2561 allele causes a minor population with a different
SD1/SD2 hinge conformation, and alters the tertiary structure
of dimers which could support dimer stem opening at lower
shear rates.12 Previously, shear-dependent functions were
shown for the VWFA1 and A2 domains. Our data now indicate
that the C-domain-encompassing stem region of VWF also
functions inresponsetoshear force (►Fig. 1C).However,deeper
insight into the biophysical properties of this part of the VWF
protein as well as the mechanisms by which it influences
platelet binding is lacking. We thus strived to better elucidate
the functional properties of the VWF stem region and
performed a database search for further SNPs in the C4 domain,
and chose to investigate the rather rare missense variant p.
Pro2555Arg (rs915754316; minor allele frequency 0.00007;
https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?
rs=915754316) due to its proximity to Phe2561 in the VWF C4
domain structure (►Fig. 1B). SinceVWFsequencing isgenerally
only performed in patients with bleeding symptoms to date, no
clinical phenotype has been reported for this variant yet.
To explore possible functional consequences of p.
Pro2555Arg, we performed extensive functional, structural,
and biophysical studies and show that this variant possesses
prothrombotic properties different from p.Phe2561Tyr. p.
Pro2555Arg is the first VWF variant which increases platelet
aggregate size (AS). The underlying mechanism is shear-
dependent and independent of fibrinogen (fb).
These data show that mutations in the VWF stem region
can enhance VWF’s prothrombotic properties and suggest
that more such variants exist representing a novel risk factor
for thromboembolic disease.
Methods
Protein Expression, Purification, and Quantification
HEK293cell lines, stablyexpressingeither full-lengthwild-type
VWF (wtVWF), p.Pro2555Arg, both variants after co-transfec-
tion, or control variant p.Asp2509Glu with an inactivated RGD
sequence, were derived from transiently transfected HEK293
cell clones as described.10,13
Wtandp.Pro2555ArgD4N-CK(residues1873–2813,UniProt
P04275)were recombinantly expressed in HEK293T cells using
the pXLG vector, which contains an N-terminal secretory
signal peptide PSG1 (pregnancy-specific β1-glycoprotein 1)
and aC-terminalHis6-tag. The cellswere transfected transiently
using polyethylenimine, and the D4N-CK protein was secreted
into the medium. Ni-Sepharose Excel beads (GE Healthcare)
were mixed with the harvested medium and the protein was
elutedwith 300mMimidazole. The elutedproteinwas dialyzed
conformations exhibiting increased hinge flexibility and slow conformational ex-
change. The dimeric protein becomes disordered and more flexible. Our data suggest
that the GOF does not affect the binding affinity of the C4 domain for GPIIb/IIIa.
Instead, the increased VWF dimer flexibility enhances temporal accessibility of platelet-
binding sites. Using an interdisciplinary approach, we revealed that p.Pro2555Arg is
the first VWF variant, which increases platelet aggregate size and shows a shear-
dependent function of the VWF stem region, which can become hyperactive through
mutations. Prothrombotic GOF variants of VWF are a novel concept of a VWF-
associated pathomechanism of thromboembolic events, which is of general interest
to vascular health but not yet considered in diagnostics. Thus, awareness should be
raised for the risk they pose. Furthermore, our data implicate the C4 domain as a novel
antithrombotic drug target.
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Fig. 1 VWF and C4 domain structure and VWF-variant:platelet integrin binding under static and flow conditions. (A) Schematic representation
of the domain structure of a VWF monomer. (B) Structure of the C4 domain showing the two subdomains SD1 (light gray) and SD2 (darker gray),
with the GPIIb/IIIa binding RGDmotif, SD1/SD2 hinge residue, Pro2555, Tyr2561, and disulfides shown as sticks. (C) Schematic representation of
a VWF dimer in the bouquet conformation with a closed C-domain stem region. (D) Recombinant wtVWF (white), p.Pro2555Arg (black), and
negative control p.Asp2509Glu (gray), in which the C4 RGD sequence is inactivated, were incubated in microtiter wells with immunoadsorbed
GPIIb/IIIa purified from platelets. Bound VWF was detected using an HRP-conjugated anti-VWF antibody. Presented is % binding relative to
wtVWF set to 100%. (E) Immunoadsorbed recombinant wtVWF (white), p.Pro2555Arg (black), and both variants co-expressed (checkered) were
incubated with HEK293 cells stably expressing a constitutively active mutant of GPIIb/IIIa. Bound cells were detected using mouse anti-GPIIb/IIIa
and a polyclonal HRP-coupled goat anti-mouse secondary antibody. The data represent the mean values SEM of three independent
measurements. Unpaired t-test: p< 0.001. (F) Recombinant single wtC4 domain (circles), p.Pro2555Arg (squares), negative controls AGA-C4
(p.Arg2507Ala_Asp2509Ala, diamonds), and EGE-C4 (p.Arg2507Glu_Asp2509Glu, triangles) in increasing concentrations were incubated with
immobilized GPIIb/IIIa. Mean values SEM of three to four independent experiments are shown. (G–I) To investigate platelet aggregation under
shear flow conditions, whole blood was washed, and plasma was replaced with VWF-deficient VWD type 3 plasma. After addition of 25 µm/mL of
either wtVWF (white) or p.Pro2555Arg (black) (I), cone and plate(let) aggregometry (CPA) was performed at 1,800 s1 for 2minutes. Aggregates
were stained using May-Grünwald solution. Seven pictures per test were recorded employing a build-in microscope and camera and analyzed
using the IMPACT-R image analyzer software. One representative image for p.Pro2555Arg and wtVWF are shown in (G) and (H), respectively.
Each test was performed in duplicates. Mean values SEM of three independent experiments are shown. Unpaired t-test: p< 0.001). n.s.: not
significant; SEM, standard error of the mean; VWD, vonWillebrand disease; VWF, vonWillebrand factor; wtVWF, wild-type vonWillebrand factor.
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against phosphate buffer, before being concentrated and puri-
fied using Superdex 200 Increase 10/300 GL (GE Healthcare) in
20mMHEPES pH 7.5, 150mM NaCl, 1mM CaCl2, 1mMMgCl2.
Wt and p.Pro2555Arg C1-CTCK (residues 2256–2813)
domain constructs were expressed as fusion proteins contain-
ing a His-tag as previously described.10 Secreted proteinswere
loaded onto a XK26 column packedwith Nickel-NTA resin (GE
Healthcare, Marlborough, Massachusetts, United States) using
aBioCADSprintHPLCsystem(PerSeptiveBioSystems,Framing-
ham, Massachusetts, United States). Column-bound proteins
werewashedwith250mLof 25mMimidazole and elutedwith
1M imidazole (both solutions: 1M NaCl and 100mM
Tris/HCl, pH 7.4), followed by dialysis for 40hours into 24L
of 150mM NaCl, 10mM sodium phosphate, pH 7.4.
Wt and p.Pro2555Arg single C4 domains (residues 2497–
2577) were generated using similar methods as previously
described.12 Samples for nuclear magnetic resonance (NMR)
wereprepared in20mMsodiumphosphatepH6.5, for circular
dichroism (CD) in 10mM sodium phosphate pH 7.4, for small-
angle X-ray scattering (SAXS) in 20mM Tris-HCl pH 7.5,
150mMNaCl. Sample conditions fulfillingmethod-dependent
requirements necessitated the use of different buffer compo-
nents and pH values.
Static GPIb and GPIIb/IIIa Binding Assays
Comparative binding of recombinant full-length wtVWF, p.
Pro2555Arg, and negative control variant p.Asp2509Glu to
isolated GPIIb/IIIa was assessed by an enzyme-linked-immu-
nosorbent assay (ELISA) using GPIIb/IIIa isolated from plate-
lets14 and by a cell-based assay, employing HEK293 cells
expressing constitutively active platelet GPIIb/IIIa at their
surface. Development and validation of the latter assay were
previously described.15 Binding of the single C4 domain to
GPIIb/IIIa was investigated as previously described.12 VWF:
GPIbα binding measurements were performed as previously
described.16 All binding assays were performed under non-
saturating conditions with equal concentrations of wtVWF
and the respective variants, allowing the detection of eventual
increased binding of GOF mutants.
Cone and Plate(let) Aggregometry
Cone and plate(let) aggregometry (CPA) was performed
employing the IMPACT-R device (Matis Medical Inc., Beersel,
Belgium)with cones and polystyrenewells as provided in the
Impact-R Test kit, according to the manufacturer’s instruc-
tions. Whole blood was washed as previously described17 to
remove the donor’s plasma VWF, which was replaced by
plasma from an adult patient with VWD type 3, who has a
nondetectable VWF antigen (VWF:Ag) but normal fb levels
(determined by radial immunodiffusion). The same batch of
plasma was used for all CPA experiments; therefore, the fb
concentration was always 3.94 g/L. Then either wtVWF or p.
Pro2555Arg was added and CPA was performed at 1,800 s1
for 2minutes. In previous studieswe determined the optimal
concentration for sufficient aggregate formation of wtVWF
in CPA experiments, when using recombinant protein in
washed blood, to be 25 µg/mL. To receive comparable data,
we always used this same concentration for wt and mutant
VWF. Aggregates were stained using May-Grünwald
solution. Seven pictures/test were recorded employing a
build-in microscope and camera and analyzed using the
IMPACT-R image analyzer software. Each sample was mea-
sured in duplicates in three independent experiments.
Microfluidic Assays
Functional characterizationofVWF-inducedcollectivenetwork
formation18 under high-shear conditionswas performed in air-
pressure-driven microfluidic channels (Bioflux, San Francisco,
California, United States; width: 350µm, height: 70µm) coated
with 50 µg/mL of either recombinant wtVWF, p.Pro2555Arg, or
p.Asp2509Glu as previously described.19 Citrated whole blood
was washed and platelets fluorescently stained as published.19
Absence of fb after following the washing protocol was
confirmed by radial immunodiffusion. The concentration was
below the detection limit of 0.5g/L. Washed blood, including
200,000 platelets per µL, 45%washedhematocrit, and10 µg/mL
of either wtVWF, p.Pro2555Arg (with or without addition of
1.3 µL/mL abciximab [ReoPro, stock concentration: 2mg/mL;
Centocor, now Janssen Biotech Inc., Horsham, Pennsylvania,
UnitedStates)], orp.Asp2509Glu,wassubjectedtoshear rates in
the range of 500–4,000s1 (with a nominal shear rate precision
of 36s1), which were increased in stages of 500 s1
every minute during experiments. For the experiments in the
presenceof fb,washedhematocrit andplateletswerebrought to
theoriginalvolumewith thesameVWDtype3plasmaalsoused
for the CPA experiments and 10 µg/mL of the respective VWF
variants was added. Live cell fluorescence movies were taken
with eight frames/s. At least four independent experiments
were performed for each group. For image analysis and rolling
AS quantification, we used the ZEN software (Zeiss AG, Jena,
Germany) and the open-source software ImageJ (V. 1.46r,
National Institute of Health, Bethesda, Maryland, United
States).20 The study was conducted in conformity with the
Declaration of Helsinki and to the International Conference on
Harmonization of Technical Requirements for Registration of
Pharmaceuticals for Human Use Guidelines (www.ich.org),
accessed in August 2018. Blood donation of volunteers was
approved by the Ethics Committee of the Medical Faculty
Mannheim, Heidelberg University (Mannheim, Germany). Ap-
propriate informed consent was obtained from all subjects.
Circular Dichroism Spectra
All protein concentrations were determined on a UV2101PC
spectrophotometer (Shimadzu, Kyoto, Japan) after centrifu-
gation of the solutions at 60,000 g at 4°C for 10 or
20minutes to remove potential protein aggregates. The
extinction coefficients used for C4 and C1-CTCK were
11,260 and 41,515 L mol1 cm1 and were calculated from
the number of tryptophan and tyrosine residues.
CD spectra were recorded at 25°C on an Aviv Biomedical
Model 420SF CD spectrophotometer. Spectra in the far-
ultraviolet (far-UV) range (200–260nm)were recorded using
a 1mmquartz cellwith an integration time of 60 seconds and
band- and step-widths of 1 nm. Near-UV CD spectra were
recorded using either a 10 cm cylindrical quartz cell (for both
C1CTCK proteins) or a 0.2 or 1 cmquartz cell (both for wtVWF
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and p.Pro2555Arg C4, respectively). The integration timewas
60 or 120 seconds and band- and step-widths were 1 nm. All
spectra were corrected for the signal of the corresponding
buffer and converted to mean ellipticity per amino acid
residue.
Small-Angle X-Ray Scattering
SAXS datawere collected at EMBL beamline P12 at the PETRA
III storage ring (DESY, Hamburg, Germany) using a 2MPilatus
pixel detector (DECTRIS) with a distance of 3.1 m. D4N-CK
constructs were measured at 0.6 to 1.2mg/mL, in 20mM
HEPES pH 7.5, 150mMNaCl, 1mMCaCl2, 1mMMgCl2. Single
C4 constructs were measured at 3.6 to 4.6mg/mL in 20mM
Tris-HCl pH7.5, 150mMNaCl. Data collectionwasperformed
with standard batch-mode setup at 20°C with a total expo-
sure time of 1.5 seconds (recorded as 3050ms frames) and
subtracted by matching buffer scattering. Analysis of the
scattering data was performed using programs from the
ATSAS 2.8.4 package.21 The forward scattering I(s) is plotted
against s, where s¼4πsinu/λ, with 2u being the scattering
angle and λ the X-raywavelength (1.24 nm; 10 keV). The radii
of gyration (Rg) were calculated from the Guinier approxi-
mation using PRIMUS.22 GNOM23 was used to obtain the
pairwise distribution function p(r), and to calculate the
maximum particle dimension (Dmax).
NMR Spectroscopy
Resonance assignment of backbone amide proton/nitrogen
resonances of p.Pro2555Arg-C4 was achieved by transferring
wtVWF-C4 assignments12 and tracing peak shifts with regard
to peak positions in wtVWF-C4. The introduced arginine in p.
Pro2555Arg-C4 and surrounding residues exhibited large
chemical shift perturbations compared to wtVWF-C4, thus
causing ambiguities in peak tracing. These ambiguities were
resolved using sequential HN-Hα-1 nuclear Overhauser effects
(NOEs) derived from a 15N-NOESY-HSQC experiment.
The NMR relaxation experiments on wtVWF-C4 from Xu
et al (2019)12 were repeated for p.Pro2555Arg, and a sum-
mary is presented here. All experiments were carried out at
298Kon Bruker Avance III NMR spectrometers (600, 700, and
800MHz) and a Bruker DRX NMR spectrometer (500MHz);
600 and 800MHz spectrometers are equippedwith cryogen-
ic triple resonance gradient probe heads. The buffer compo-
sition was the same as for wt (20mM sodium phosphate, pH
6.5) and a protein concentration of 250 µM was used.
Measurements of R1, R2, and 1H-15N heteronuclear NOE
experiments for the VWF-C4 p.Pro2555Arg variant were
acquired using standard pulse sequences and relaxation
delays specified in ►Table 1. To assess the micromillisecond
dynamics for certain residues, Carr–Purcell–Meiboom–Gill
(CPMG)24,25 relaxation dispersion experiments were
conducted using a previously published pulse sequence.26
Effective fields of νCPMG¼1/(4τCP) were used, where 2τCP is
the interval between refocusing pulses with frequencies
shown in ►Table 1. All spectra were processed with
NMRPipe27 and analyzed using Sparky28 and PINT.29,30
ROTDIF31was employed to determine the diffusion tensor
from R2/R1 ratios and used to compute the rotational corre-
lation time τc. After excluding residues with hetNOE values
<0.65, the axially symmetric diffusion model exhibited the
minimal best fit.
Molecular Dynamics Simulations
Atomistic and explicit-solvent molecular dynamics (MD)
simulations were conducted using GROMACS software,32
version 5.1.x or 2016.2. The simulation methodology used
here is based on Xu et al.12 Note that the published NMR
ensemble (6FWN.pdb) corresponds to the NMR-detectable
extended conformation. To improve sampling efficiency, the
wtVWF-C4 trajectory data produced by Xu et al12 was used
instead to include both extended and bent conformations as
sampling templates.
Two independent MD protocols were performed in this
study. In one protocol, 20 snapshots were drawn and manu-
ally mutated to form p.Pro2555Arg using Visual Molecular
Dynamics software.33 This formed the starting ensemble for
CHARMM22 simulations. In the other protocol, 14 snap-
shots were drawn and manually mutated using Pymol,34
forming the starting ensemble for Amber99sb-ildn simu-
lations. Relevant simulation parameters are summarized in
►Supplementary Table S1 (available in the online version).
Results
p.Pro2555Arg Exhibits GOF Characteristics Only under
Shear Flow Conditions
Functional characterization of recombinant full-length
wtVWF and p.Pro2555Arg multimers was carried out by
Table 1 A summary of parameters used to conduct p.Pro2555Arg NMR experiments
Spectrometer frequency (MHz) Relaxation delays (ms)
R1 500, 600, 700, and 800 20, 20, 50, 100, 150, 250, 400, 500, 650, 800,
1,000, 1,300, and 1,600 (N¼13)
R2 500, 600, 700, and 800 16, 16, 32, 48, 64, 80, 96, 112, 128, 160, 192,
224, and 256 (N¼ 13)
1H–15N hetNOE 500, 600, 700, and 800 n.a. (N¼2)
Refocusing pulse frequency (Hz)
CPMG 600 and 800 33, 66, 100, 133, 200, 266, 333, 400, 466, 533,
600, 666, 800, and 933 (N¼ 14)
Abbreviations: CPMG, Carr–Purcell–Meiboom–Gill; NMR, nuclear magnetic resonance.
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measuring binding to isolated platelet GPIIb/IIIa in an ELISA
format and, additionally, by a cell-based assay using HEK293
cells, expressing the constitutively active GPIIb/IIIa variant p.
Thr588Asn.33 In both static assays, p.Pro2555Arg did not
show a significant difference in GPIIb/IIIa binding compared
to wtVWF (►Fig. 1D, E). Also, for the single C4-domain
construct, used for structural investigation, normal
GPIIb/IIIa binding was observed (►Fig. 1F). As expected,
control variants with mutations in the RGD sequence were
unable to bind GPIIb/IIIa (►Fig. 1D, F) and VWF:GPIbα
binding was unaltered by p.Pro2555Arg (►Supplementary
Fig. S1A, available in the online version).
To determine if p.Pro2555Arg exhibits shear-dependent
alterations, we performed CPA. Washed blood was supple-
mented with VWD type 3 plasma, which has no detectable
VWF:Ag but a normal fb concentration (3.94 g/L). Then either
recombinant wtVWF or p.Pro2555Arg was added and CPA
was performed. As shown in►Fig. 1(G–I), the platelet ASwas
increased by about 100% in the presence of p.Pro2555Arg
(►Fig. 1G, I) compared to wtVWF at the same concentration
(►Fig. 1H–I). Such a prothrombotic GOF characteristic was
previously only observed for VWF variant p.Phe2561Tyr.10 In
the CPA setup, the presence of the control mutant p.
Asp2509Glu, in which the GPIIb/IIIa-binding RGD sequence
is inactivated, also exhibited a somewhat increased platelet
AS compared to the presence of wtVWF (►Supplementary
Fig. S1B, available in the online version).
Our findings are in accordance with a previous study by
Wu et al,34 showing that fb can compensate for VWF in
platelet crosslinking, when the VWF-RGD sequence is
disturbed.
Since presence of fb is required for platelet aggregate
adhesion in CPA assays, we next performed a microfluidic
assay which does not require fb, to gain more insights into
the mechanism by which p.Pro2555Arg increases the size of
platelet aggregates (►Fig. 2). At lower shear rates of 500 and
2,000 s1, both variants behaved similarly, showing only
single platelets rolling along the VWF-biofunctionalized
surface. The first platelet-decorated VWF fibers emerged at
the channel surface at 2,000 s1 (►Fig. 2A, colored spots in
left panels). Above a critical shear rate of 4,000 s1, fiber-like
structures partially detached and induced the origin of large
reversible VWF–platelet collective network aggregates roll-
ing along the surface,35,36whichwere significantly increased
in size when p.Pro2555Arg was present in the reconstituted
blood (►Fig. 2A, top) at the samephysiological concentration
Fig. 2 Characteristics of VWF-induced collective network formation of wtVWF and p.Pro2555Arg at indicated shear rates. (A) Each image represents a
composition of 20 sequential frames of a live-cell fluorescencemovie taken at a frequency of eight frames per second. By subtracting identical pixels among
frames, a color-coded addition of these differential images from frame0 (blue) to frame20 (red) along the color scale, combinedwith the inverted gray-scaled
background imageof the start frame, allowsprecise detection andmotion trackingofVWF-induced collective networks. Therefore, onlymoving networksare
displayed in color enabling an exact determination of the critical shear rate. While the critical shear rate for rolling aggregate formation is the same as for p.
Pro2555Arg (upper row) andwtVWF (second row), p.Pro2555Arg shows significantly increased aggregate sizes. Themutant p.Asp2509Glu does neither affect
the critical shear rate, nor the aggregate size compared to wtVWF (third row). Nevertheless, by inhibition of GPIIb/IIIa via abciximab, the GOF effect by p.
Pro2555Arg is completely abolished (fourth row), while addition of abciximab towtVWFdoes not change its aggregate formation behavior (bottom row). The
black arrow indicates theflowdirection and corresponds to 100µm.One example outof at least four independent experiments is shown. (B andC) Computer-
assisted quantification of the collective network size at the critical shear rate demonstrates an about sixfold increase in size of the detected rolling aggregates
for p.Pro2555Arg in comparison to wtVWF. Panel (B) shows one exemplary image used for the quantification. Thewhite scale bars correspond to 100µm. (C)
Meanvalues SEMof at least four independent experiments are shown.Unpaired t-test: p< 0.001.GOF, gain of function; SEM, standard error of themean;
VWF, von Willebrand factor; wtVWF, wild-type von Willebrand factor.
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of 10 µg/mL as wtVWF. Computer-assisted quantification of
collective network size at a shear rate of 4,000 s1, the critical
shear rate for rolling aggregate formation as shown
in ►Fig. 2A, demonstrates an increase of the mean area of
detected rolling aggregates from 853µm2 for wtVWF to
5,041 µm2 in the presence of p.Pro2555Arg (►Fig. 2B, C).
These data confirm a shear-dependent GOF effect by p.
Pro2555Arg (see also ►Video 1) different from p.Phe2561-
Tyr, which showed aggregates of the same size as wtVWF but
already at 2,000 s1.10 In the absence of the plasmatic VWF
fraction, neither platelet-binding fibers nor collective net-
works are formed.10 Interestingly, in our microfluidic setting
mimicking the early phase of rolling aggregate formation,
mutant p.Asp2509Glu did not exhibit any significant differ-
ence, neither in the critical shear rate nor in the size of
aggregates, compared to wtVWF. This finding indicates that
the initial occurrence of aggregate formation does not nec-
essarily require VWF–GPIIb/IIIa interactions. To test the
hypothesis that p.Pro2555Arg nevertheless mediates the
increase in AS via a GPIIb/IIIa-associated mechanism, we
next added the GPIIb/IIIa-blocking antibody abciximab to the
microfluidic experiments and found that, upon inhibition of
GPIIb/IIIa, the GOF effect by p.Pro2555Arg was completely
abolished (►Fig. 2A, compare first and fourth rows).
Video 1
Characteristics of VWF-induced collective network
formation of p.Pro2555Arg. Excerpts of a representa-
tive live cell fluorescence movie (bottom) with the
corresponding computer assisted analysis of the col-
lective network size (top) for p.Pro2555Arg. Themovie
was taken at a frequency of eight frames per second.
During the experiment, the shear ratewas increased in
stages of 500 s-1 up to 4,000 s-1. For better illustra-
tion, excerpts at shear rates of 1,000, 2,000, 3,000 and
4,000 s-1 are depicted separated by fading out. At the
critical shear rate of 4,000 s-1 huge collective networks
of p.Pro2555Arg and platelets are formed rolling along
the surface of the channel. The current shear rate in s-
1 is stated in the upper left (‘rate:’), the current time
frame as indicated (‘f:’). Note that the exemplary image
shown in ►Fig. 2B was taken at frame 1,140.
Online content including video sequences viewable at:
https://www.thieme-connect.com/products/ejour-
nals/html/10.1055/a-1344-4405.
To test whether fb plays a role in this GOF effect of p.
Pro2555Arg, we further repeated the microfluidic experi-
ment in the presence of fb by employing the VWD type 3
plasma used for the CPA experiments. We found a significant
increase in size of reversibly formed VWF–platelet collective
network aggregates in both the absence and the presence of
physiological fb concentration above the same critical shear
rate of 4,000 s1 (from 1,143 µm2 for wtVWF to 4,610 µm2 in
the presence of p.Pro2555Arg, see ►Supplementary Fig. S2,
available in the online version). These data indicate that the
GOF effect of p.Pro2555Arg is not promoted by fb and further
suggest that p.Pro2555Arg does not lead to enhanced aggre-
gation and platelet activation with subsequent fb release.
This observation is in line with previous findings by Con-
stantinescu-Bercu et al,37 who showed that VWF binding to
platelet GPIbα via the VWF-A1 domain leads to platelet
“priming,” which is characterized by GPIIb/IIIa activation
without full platelet activation.37–39 In conclusion, p.
Pro2555Arg seems to mediate increased agglutination dur-
ing this priming phase of platelet activation in a fb-indepen-
dent manner. Furthermore, the GOF effect of p.Pro2555Arg is
also present at normal plasma fb antigen and could therefore
be physiologically relevant in a carrier of the p.Pro2555Arg
mutation.
Circular Dichroism Spectra Reveal That p.Pro2555Arg
Affects the Dimeric Structure of the C-Terminal Stem
Region
To assess the impact of p.Pro2555Arg on the secondary
and tertiary structures of the monomeric single C4 do-
main and the dimeric domain construct C1-CTCK, far- and
near-UV CD spectra were recorded for wt and p.
Pro2555Arg C4 and C1-CTCK (►Fig. 3). Within the single
C4 domain, p.Pro2555Arg has no detectable effect
on secondary and tertiary structures as the far- and
near-UV CD spectra are identical to those of the wt protein
(►Fig. 3, top panels). The far-UV CD spectrum of C4 shows
a maximum at 230 nm and a minimum at 206 nm for both
wtVWF and p.Pro2555Arg. The overall shape of the spec-
trum is typical for a protein that is dominated by β-strand
and random coil structural elements.
Fig. 3 Circular dichroism spectra of C4 andC1CTCK. Far-UV (left) and near-
UV (right) circular dichroism spectra are shown for wild-type (●,&) and p.
Pro2555Arg (●, &) C4 (top) and C1-CTCK (bottom). All spectra were
recorded at 25°C, corrected for the signal of the corresponding buffer and
converted to mean ellipticity per amino acid residue ([Θ]MRW). UV,
ultraviolet.
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In contrast to themonomeric C4domain, p.Pro2555Arghad
a significant effect on the dimeric C1-CTCK construct, which
contains the stem region of VWF (►Fig. 3, bottompanels). The
far-UV CD spectrum shows a massive loss of secondary struc-
ture content in themutant, which indicates an enhanced local
disorder in p.Pro2555Arg C1-CTCK. An estimation of
the secondary structure content using the CD spectrum
deconvolution tool BeStSel40 confirms this assessment as it
reports a reduction of about 20% in ordered secondary struc-
ture content and a shift toward random coil. The near-UV CD
spectrum of p.Pro2555Arg C1-CTCK also differs from that of
the wt protein and indicates an altered tertiary structure.
Taken together, the CD spectra indicate that p.Pro2555Arg
has no structural effect within the monomeric C4 domain,
but it alters the secondary and tertiary structures of the
dimeric C1-CTCK construct.
SAXS Analysis Reveals Increased Flexibility of the VWF
Stem Region in p.Pro2555Arg
To further investigate the effect of the p.Pro2555Arg variant on
the overall shape and size of the VWF proteins, we performed
SAXS analysis on both single C4 domains and D4N-CK-dimers
(►Fig. 4 and►Table 2). Similar to the results acquired from the
CD spectra, the single C4 domain remains unaffected by the p.
Pro2555Arg mutation. No detectable differences can be
seen from the scattering curves. The Kratky plot indicates an
extended fold, which agrees with the NMR structure and MD
simulationshownbelow. Furthermore,wecalculated theRg and
Dmax values using the pairwise distance distribution function p
(r), which are in good agreement with the NMR structure and
there isnoobservabledifferencebetweenwtandp.Pro2555Arg.
However, significant changes are visible in the context of the
dimeric D4N-CK domain construct. The p.Pro2555Arg muta-
tion, as indicated by the differences in the scattering at small
angles, introducesan increasedsizeof themoleculeasshownby
increased Rg (1.4-fold) and Dmax (1.6-fold) compared to wt
(►Fig. 4D, zoomed-in inset). In line with the CD data, the
mutation affects the stem structure within VWF dimers. As a
possible result, the multimers could become more flexible and
more accessible to GPIIb/IIIa binding upon stemopening,which
could ultimately lead to increased sizes of platelet aggregates.
NMR Studies on the Isolated C4 Domain Reveal Local
Distortions of the p.Pro2555Arg C4 Domain Structure
and Associated Changes in Conformation Dynamics
The CD and SAXS analysis above eliminated large-scale struc-
tural changes of the isolated C4 domain as a plausible explana-
tion for the increasedASobserved in the shearflowassays. This
leaves dynamics as the next candidate. Thus, we conducted
NMRspin relaxationexperimentsonthe isolatedp.Pro2555Arg
Fig. 4 SAXS showing that p.Pro2555Arg (P2555R) affects the stem structure of VWF. Scattering curve (A), Kratky plot (B), and pair distance
distribution function p(r) (C) of the single C4 domain as wt (blue) and p.Pro2555Arg variant (magenta) showing near identical profiles. For D4N-
CK dimers, however, differences in the small-angle region (s< 1 nm-1, zoomed-in insets) between wt (black) and p.Pro2555Arg (red) can be seen
in the scattering curve (D) and Kratky plot (E), while the p(r) function (F) shows larger Dmax and a more flexible conformation for the p.
Pro2555Arg variant compared with wtVWF. SAXS, small-angle X-ray scattering; VWF, von Willebrand factor; wt, wild type.
Table 2 Structural parameters of VWF C4 and D4N-CK wt
versus p.Pro2555Arg calculated from SAXS p(r) function
Rg
a (nm) Dmax
b (nm)
C4wt 2.1 7.8
C4 p.Pro2555Arg 2.1 7.8
D4N-CK wt 8.8 35
D4N-CK p.Pro2555Arg 12.4 56
Abbreviations: SAXS, small-angle X-ray scattering; VWF, von Willebrand
factor; wt, wild type.
aRg: radius of gyration.
bDmax: maximum particle dimension.
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VWFC4domain for comparisonwithpublishedwtVWFdata.12
The comparison of the wt and p.Pro2555Arg 1H-15N HSQC
spectra (►Fig. 5A–C) on the one hand confirms a globally
unperturbed C-domain fold in agreement with the SAXS and
CD data above, but on the other hand reveals subtle but
extensive local perturbations throughout the three β-strand
architecture of C4’s SD2, indicated by shifts in multiple peak
positions. Moreover, residual peak intensities at the wt loca-
tions suggest a slow conformational exchange between this
distorted conformationwith awt-likeminor population. Given
that the wt orientation of Pro2555 points inward against the
other β-strands, this suggests that Arg2555 stabilizes a dis-
torted conformation of the entire SD2 without perturbing the
overall architecture.
Fig. 5 NMR structural and dynamics perturbations of p.Pro2555Arg relative to wild type. (A) Overlapped 1H–15N HSQC spectra of the wild-type
C4 (red) and p.Pro2555Arg (blue). Peaks with significant shifts or loss of intensity have been labeled. Slow exchange between wtVWF-like and p.
Pro2555Arg-like conformations can be inferred from weak p.Pro2555Arg peaks at wild-type positions and strong peaks at p.Pro2555Arg
positions. (B) Example of the p.Pro2555Arg structure, showing residues with significant structural perturbations (gray-blue spheres) and residues
with millisecond dynamics switching between multiple conformations (transparent green spheres). (C) Chemicalshift perturbation (CSP) plot
showing the residue-wise structural change of p.Pro2555Arg compared to wtVWF C4, where values over 0.05 indicate significant change in
local environment. (D) Fast nanosecond dynamics of 1H–15N bonds for wtVWF (orange-red) and p.Pro2555Arg (green-blue) C4 domains, via R2/R1
ratios measured at four magnetic fields. (E) Millisecond conformation dynamics for four example residues in p.Pro2555Arg, as measured by
CPMG relaxations at 800MHz. Dynamics of 11 residues are shown in Supplementary Fig. S3. CPMG, Carr–Purcell–Meiboom–Gill; NMR, nuclear
magnetic resonance; wtVWF, wild-type von Willebrand factor.
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Local dynamics of the C4 backbone residues were further
investigated in NMR 15N-spin-relaxation and CPMG experi-
ments (►Fig. 5D, E). The overall similarity of spin-relaxation
profiles at multiple fields shows that the majority of residues
remain oriented in the same direction relative to the protein.
The observed isotropic tumbling times τc are also comparable:
wt exhibits a τc of 7.30.1ns andp.Pro2555Arg exhibits a τc of
8.00.1ns. These further confirm that the extended C4
conformation is the dominant population. However, p.
Pro2555Arg experiences additional and altered exchange dy-
namics both at the hinge and at proximal sites in SD2 (green
spheres in►Fig. 5B),whichappear to consistentlyexchangeon
a timescale of approximately 500 s1 (►Supplementary
Fig. S3, available in the online version).
Molecular Dynamics Simulations Suggest Conformation
Switching Stabilized by Alternate Arg2555 Charge
Interactions
In wtVWF-C4, Pro2555 points inward into the core of SD2.
Replacement of this proline by Arg2555 should therefore
create steric clashes (►Fig. 6A). These considerations were
investigated using MD simulations of p.Pro2555Arg-C4 in
two independent force fields, CHARMM22 and Amber99sb-
ildn, to corroborate findings. The overall similarity of both
results led us to present only the CHARMM data, with the
AMBER data included in ►Supplementary Figs. S4 to S7
(available in the online version). We additionally include
published data of wtC4 from Xu et al12 for comparison.
The simulated trajectories confirm that p.Pro2555Arg does
not perturb the relative population of extended versus bent C4
populations, as indicated by a dominant population at a hinge
angle around 180° (►Fig. 6A, B). These extended structures
are in overall agreement with SAXS (►Fig. 4) and NMR
(►Fig. 5D) data. Next, we investigated the spatial location of
the long Arg2555 side chain relative to SD2. By measuring a
dihedral angle ωArg2555 using Val2554 and Val2556 to define
the axis of rotation, we show that the Arg2555 side chain
populates threedistinct arrangements:behind theβ-sheet and
nearby the C-terminal Glu2577; pointing directly away from
SD2; and a minuscule population in front of the β-sheet
Fig. 6 Simulatedglobal and local dynamics of wtVWFandp.Pro2555ArgC4domains. (A) Representative structure of wtVWF-C4 showing its chargednetwork,
where relevant acidic, basic, and cysteine residues are displayed as sticks. C4’s hingemotions are defined using four centers of mass, spanning residues 2497–
2547 (most of SD1); 2546–2548 (backbone hinge joint, green), 2528–2570 (disulfide hinge joint, yellow); and 2548–2577 (SD2). The two hinge joints define an
axis of rotation and SD1 defines the zero angle. (B) Overall conformation of C4 SD1 and SD2 for wtVWF (upper) and p.Pro2555Arg (lower) depicted using the
hinge and pinch angles defined in (A). (C) Orientation distribution of the Arg2555 side chain relative to SD2 depicted using a dihedral angleωArg2555. The axis of
rotation isdefinedbyVal2554andVal2556,andSD2defines thezeroangle. Eachobservedpeak is illustratedbyanexamplep.Pro2555ArgSD2conformation. For
a movie of an example transition from β sheet to α-helical Ramachandran of VWF-C4-p.Pro2555Arg, please refer to►Video 2. (D) Ramachandran angle ψ
distribution of Val2554 and Pro/Arg2555, showing the appearance of an α-helical backbone for p.Pro2555Arg. wtVWF, wild-type von Willebrand factor.
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(►Fig. 6C, ►Video 2). Each arrangement corresponds to a
distinct charge network with neighboring SD2 residues. The
conformational switching is further enabled by backbone
flexibility not possible in wtVWF, where residues Val2554,
Arg2555, and Val2556 exhibitα-helical conformations around
Ramachandranψ-angles of20° (►Fig. 6D,►Supplementary
Fig. S6, available in theonlineversion). As a consequenceof the
increased dynamics in the vicinity of Arg2555, the overall
length of SD2 along its β-sheets is slightly contracted
(►Supplementary Fig. S7, available in the online version).
Taken together with observed NMR dynamics, p.Pro2555Arg
exists in an equilibrium of at least two SD2 conformations
stabilized by different charge networks.
Video 2
Example transition (0:15-0:25) from beta-sheet to
alpha-helical ramachandran of VWF-C4-p.
Pro2555Arg, composed using VMD and ffmpeg. Repli-
cate #2 from 0-30ns simulation time is observed at
0.60ns/sec and 60 fps. The SD2 backbone reference
frame is used to remove global motions. Trajectories
have been smoothed in VMD with a half-width of 3.
Protein-protein hydrogen-bonds shown as black dot-
ted lines, using criteria of 3.0 Angs. distance and
25 degrees.
Online content including video sequences viewable at:
https://www.thieme-connect.com/products/ejour-
nals/html/10.1055/a-1344-4405.
Discussion
In this study, we identified p.Pro2555Arg to be the first GOF
variant of VWF which increases platelet AS. Our shear-based
CPA and microfluidic assays convincingly demonstrate
the underlying mechanism to be shear-force-dependent,
independent of fb and mediated through interaction of the
VWF stem region with platelet receptor GPIIb/IIIa via the
RGD sequence in the VWF C4 domain.
Structural investigations using CD, SAXS, NMR, and MD
approaches consistently support a model where the p.
Pro2555Arg mutation primarily affects the structure of the
VWF stem region in the context of a dimer. This points
toward a mechanism where the arginine disrupts the local
dimer interface and partially destabilizes the dimer organi-
zation. In the context of the multidomain VWF molecule, p.
Pro2555Arg introduces a new positive charge to a local
charged network comprising Glu2553, Lys2566, Arg2575,
and Glu2577 in the C4 domain, as well as Arg2578 and
Glu2580 at the start of C5. Together with the additional
backbone flexibility permitted by the loss of Pro2555, this
introduces a dynamic equilibrium between competing p.
Pro2555Arg conformers seen in NMR and MD. We note
that the RGD motif relevant to integrin binding lies approxi-
mately 5 nm away in SD1, which rules out a direct influence
on this motif, as confirmed by static assays. Similarly, even
though CD and SAXS suggest that the localized perturbation
leads to a more extended and disordered VWF dimer, this is
also insufficient to affect steady-state binding with
GPIIb/IIIa. As the GOF mechanism for p.Phe2561Tyr, we
suggested that the more extended dimers show an increase
in sensitivity for stem opening compared to wtVWF
dimers.10,12 Microfluidic experiments showed that this is
not the case for p.Pro2555Arg. It rather elicits an increase in
AS once opening of the zipped VWF stem is accomplished.
This novel effect is directly mediated by an influence of the
mutation on VWF–GPIIb/IIIa interaction via the C4-RGD
sequence, as blocking of the GPIIb/IIIa receptor on the
platelet surface completely abolished the GOF effect of p.
Pro2555Arg.
An explanation of this observed effect appears to lie
indirectly in the transiently altered structure and dynamics
of the C4 domain. Our NMR and MD data collected for the
isolated C4 domain show preference of a subtly distorted p.
Pro2555Arg C4 structure over a wt-like structure exchang-
ing in the slow conformational exchange regime. This
preference is likely to be influenced by the rest of the
VWF chain as the dimer switches between zipped and
open states.
Our current working hypothesis is that the distorted
conformations sampled by the isolated p.Pro2555Arg-C4-
domain are absent under static conditions, due to stabili-
zation of the wt conformation by the rest of VWF. Howev-
er, disruption of the resting dimer under shear flow
enables distorted p.Pro2555Arg-C4 to manifest. This hin-
ders the reformation of zipped dimers and thus indirectly
increases the temporal availability of RGD domains for
GPIIb/IIIa binding, leading to increased VWF–platelet
crosslinking.
Our CPA experiments and a previous study by Wu et al,34
indicated that inactivation of the VWF-RGD sequence makes
more GPIIb/IIIa receptors available for binding by fb, explain-
ing the overcompensation of platelet agglutination by fb in
the CPA experiments with mutant p.Asp2509Glu. Variant p.
Pro2555Arg has the same affinity for GPIIb/IIIa as wtVWF
under static conditions. Therefore, one could expect that
both compete out fb in the samemanner; however, this is not
the case. Our data suggest the following explanation for this
observation: the increased temporal availability of the RGD
sequence for GPIIb/IIIa binding by the p.Pro2555Arg substi-
tution is induced by shear forces. Hence, flow conditions are
required to activate the GOF effect of p.Pro2555Arg. Upon
activation by the same critical shear rate as required for
wtVWF, the extended lifetime of available GPIIb/IIIa-binding
sites in p.Pro2555Arg leads to prolonged platelet binding.
Consequently, less receptors are available for fb to bind and
therefore fb is competed out more by p.Pro2555Arg than by
wtVWF.
It has previously been suggested that neutrophil oxidants
will render newly secreted VWF uncleavable and alter the
largestplasmaVWFformstobecomehyperactiveandresistant
to proteolysis by ADAMTS13 due to methionine oxidation
under inflammatory conditions.41 Such a mechanism can,
however, also be ruled out for the C4 domain as it does not
contain Met residues.
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In order to better connect the altered behavior in shear
flow assays with our structural data, high-resolution struc-
tural and dynamics data of the C4 domain in context of
longer constructs (e.g., C1-CK)would be necessary. However,
this is not possible as these constructs would exceed the size
limitation of NMR and are likely too flexible for other
techniques such as cryo electron microscopy. Nevertheless,
as the overall structure of the C4 domain is not perturbed in
isolation, the mechanistic basis of the different behavior
under shear flow must lie in the altered dynamics of the p.
Pro2555Arg variant compared to wtVWF C4 domains inves-
tigated here by NMR and MD simulations.
The extensive similarities between wtVWF and p.
Pro2555Arg functions under static conditions, echoing that of
the previously published p.Phe2561Tyr report, highlight an
inadequacy of such approaches for VWF research. Since many
structural analyses are currently only feasible under static
conditions, we strongly emphasize the necessity of incorporat-
ing variable shear flow conditions as much as possible into
future assays and techniques. Investigation of the force-depen-
dentbehaviorof thedifferentvariantswill requirefuturestudies
with a shear force chamber set-up. Such development has been
initiated, for example, by utilizing a rheometer set-up or a
microfluidic channel, creating shear force and pressure for in
situ, time-resolved SAXS experiments.42,43 More elaborated
computational approaches could include simulating the force
environment in the blood stream. As future advances expand
ourability to introduceshearandelongationalflowtostructural
investigations, we hope to fully unravel the rich secrets of this
key coordinator of hemostasis.
Summarizing, our data show that the VWF stem region
has specific flow-dependent functions in hemostasis in
concert with GPIIb/IIIa and suggest that alteration of this
interaction by mutations in the C4 domain can lead to an
increase in VWF’s hemostatic activity. Thus C4-domain
mutants can have opposite characteristics compared with
VWF variants with mutations in the other domains, which
rather exhibit a decrease in hemostatic activity and thus
induce the bleeding disorder VWD. Even GOF mutations in
the A1 domain, counterintuitively, lead to bleeding symp-
toms due to spontaneous binding to platelets via GPIbα and
depletion of platelets and VWF from the circulation.44 In
contrast, the presence of C4 GOF variants of VWF could
increase susceptibility and/or severity for thromboembolic
events as these VWF variants are hyperactive in a shear-
dependent manner. For variant p.Phe2561Tyr, we indeed
recently showed that it can increase the risk of early and
repeated MIs by lowering the threshold for shear-induced
platelet binding.10 Variant p.Pro2555Arg does not lower this
threshold but it increases temporal availability of RGD
domains for GPIIb/IIIa binding compared to wtVWF and
therefore enhances VWF–platelet complex formation at the
normal critical shear rate. Thus, in an event which normally
leads to VWF activation, i.e., vessel injury, p.Pro2555Arg
might increase the risk of thrombosis. This prothrombotic
GOF effect also explains why p.Pro2555Arg has not been
associated with a clinical phenotype yet, as genetic analysis
of VWF in general only performed in patients with bleeding
symptoms.
At elevated shear rates, stable platelet aggregation is
primarily dependent onVWFbinding toGPIIb/IIIa.45–47 Since
vascular diseases, such as atherosclerosis and MI, are associ-
ated with increased shear rates, this interaction becomes
especially important under these conditions. Furthermore,
bacterial and viral infections are associated with a strong
inflammatory response, which activates the endothelium
thereby strongly increasing VWF levels. Recently, it has
been shown that patients with COVID-19 develop hyperco-
agulability with elevated levels of VWF, coagulation factor
VIII, and fb.48
After now revealing that GOF variants of VWF exist, which
could even further intensify a state of hypercoagulability, it is
thus of paramount importance to increase awareness of such
VWF variants and to gain more mechanistic insights into the
biophysics of the VWF stem region encompassing the C-
domains. Further, it now becomes increasingly clear that
normal functionality of the VWF stem region is of utmost
importance to prevent vascular disease and thrombotic
complications. Our data show that changes in the mechano-
sensitivity and/or dynamics of the VWF stem can increase
platelet aggregation and thus pose a risk of thromboembolic
events. In the future, investigation of the VWF C4 domain
should thus be considered as an additional diagnostic tool to
explain such events, especially in individuals in whom they
cannot be attributed to the common risk factors.
Intriguingly, our results suggest that VWF-C4 could be a
promising target to develop novel strategies to treat or
prevent such events. Direct inhibition of integrin receptor
GPIIb/IIIa on the platelet surface blocks interaction with all
protein binding partners containing RGD sequences andmay
cause life-threatening bleeding. The use of GPIIb/IIIa block-
ing antibodies as antithrombotic drugs is thus declining.
Inhibiting the interaction of VWF with GPIIb/IIIa by specifi-
cally reducing binding of the VWF C4 domain to platelets
could be a promising alternative.
What is known about this topic?
• It iswell established thatmutations in theVWFgene can
lead to loss of hemostatic activity and von Willebrand
disease.
• High antigen levels of vonWillebrand factor (VWF) can
possess prothrombotic properties.
What does this paper add?
• We identified p.Pro2555Arg to be the first gain-of-
function variant of VWF which increases aggregate
size in a shear flow- and GPIIb/IIIa-dependent manner.
• Our interdisciplinary approach reveals that the p.
Pro2555Arg mutation in the C4 domain increases
VWF dimer flexibility, thereby enhancing accessibility
of platelet-binding sites.
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